Last reviewed · How we verify

PINAVERIUM

Phase 2 active Small molecule ✓ Verified May 2026 Quality 24/100

PINAVERIUM is a pinaverium drug. It is currently in Phase 2 development.

PINAVERIUM works by relaxing smooth muscle in the gastrointestinal tract, reducing spasms and cramping.

PINAVERIUM is a small molecule with the chemical name pinaverium bromide, used as an intervention in clinical trials for conditions such as Bile Duct Diseases, Sphincter of Oddi Dysfunction, and Irritable Bowel Syndrome. It has been studied in combination with other interventions, including Vitamin C and Danshu Capsules, in clinical trials such as NCT02882451.

Likelihood of approval
15.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namePINAVERIUM
Drug classpinaverium
ModalitySmall molecule
Therapeutic areaGastroenterology
PhasePhase 2

Mechanism of action

Imagine your digestive tract as a muscular tube that moves food through your body. PINAVERIUM helps calm down the muscles in this tube, making it easier for food to pass through and reducing discomfort.

Approved indications

No approved indications tracked.

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about PINAVERIUM

What is PINAVERIUM?

PINAVERIUM is a pinaverium drug.

How does PINAVERIUM work?

PINAVERIUM works by relaxing smooth muscle in the gastrointestinal tract, reducing spasms and cramping.

What drug class is PINAVERIUM in?

PINAVERIUM belongs to the pinaverium class. See all pinaverium drugs at /class/pinaverium.

What development phase is PINAVERIUM in?

PINAVERIUM is in Phase 2.

What are the side effects of PINAVERIUM?

Common side effects of PINAVERIUM include Heart sounds, Prolonged expiration, Depressive symptom, Respiration abnormal, Appetite disorder, Sleep disorder due to a general medical condition.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing